ClinicalTrials.gg
RecruitingNCT07219238Updated Jun 17, 2026

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

A Phase 2/3 interventional study of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) in Colorectal Cancer, Gastric Cancers and Ovarian Cancers, sponsored by GE Healthcare. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by GE Healthcare · Phase 2/3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
574th of 1,932
175 · median 64
Started
2026
with 117 others
Phase 2/3
15 of 2,339
2 open now
Primary completion
2029-06
later than 540 of 628 live
Registered
2,210th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 574th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 15 in phase 2/3, reaches primary completion later than 540 of the 628 other live ones, and was the 2,210th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study.

The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.

03

Conditions studied

  • Colorectal Cancer
  • Gastric Cancers
  • Ovarian Cancers
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Peritoneal Carcinomatosis (PC)
  • Pancreatic Cancers
  • Colorectal cancer
  • Gastric cancer
  • FAPI
  • Ovarian cancer
  • 68Ga
  • PET/CT imaging
  • Diagnostic imaging
  • Diagnostic performance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ≥18 years of age
  • Participant has provided signed before any study-specific screening procedures
  • Participant has histopathologically confirmed primary colorectal, gastric or ovarian cancer or PDAC
  • Participant has known or suspected PC from the tumor of origin. Suspicion may be based on imaging or clinical findings.
  • Participant is scheduled for peritoneal surgery with curative intent, surgical exploration, or laparoscopy, with either: a. No treatment received, treatment-naïve (i.e., undergoing upfront surgery or laparoscopy) b. Completed systemic treatment (which may include neoadjuvant chemotherapy) before GEH300079 ( 68Ga) PET/CT Imaging Visit
  • Participant has (ECOG) performance status ≤2
  • Participant is able and willing to comply with all study procedures as described in the protocol

Exclusion criteria

Exclusion Criteria:

  • Participant is pregnant or breast-feeding, or sexually active and not using or not willing to use an acceptable form of from screening up to 30 days after receiving the medicinal product (IMP)
  • Participant has a known disorder that, in the opinion of the investigator, will impact the study procedures
  • Participant needs any intervention that would delay study participation
  • Participant has non-resectable extra-abdominal and/or >3 hepatic metastases on standard work up
  • Participant will not be able to complete the study, based on their anticipated
  • Participant has active bacterial, viral, or fungal infection requiring systemic antibacterial, anti-viral or antifungal therapy (topical medications are permitted)
  • Participant has renal function impairment as defined by:

    1. For Phase 2: estimated less than 60 mL/min
    2. For Phase 3: estimated glomerular filtration rate less than 30 mL/min
  • Participant has severe hepatic function impairment as defined by:

    1. (serum glutamic-oxaloacetic transaminase) and alanine aminotransferase (serum glutamic-pyruvic transaminase): ≤2.5 × (ULN; ≤5 × ULN for participants with liver metastases)
    2. : ≤1.5 × ULN or direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN
  • Participant has disease that required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic ) is allowed
  • Participant has serious co-morbidities or serious non-malignant disease that in the opinion of the investigator, could compromise participant safety and/or protocol objectives
  • Participant either received or is planning to receive any other investigational agent within the 28 days prior to the first imaging visit or during study participation (with the exception of the 3-month follow-up period)
  • Participant has known or suspected to any used in GEH300079 (68Ga)
  • Participant has severe claustrophobia, is unable to lie flat or fit into the scanner, or is unable to tolerate the PET/CT scan for any reason
  • (Phase 3 only) Participant was previously included in Phase 2 of this study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    GEH300079 (68Ga) PET/CT Injection

    Single IV bolus of GEH300079 (68Ga), target activity 3.6 MBq/kg (150-300 MBq). PET/CT scan at 60 ±5 min post-dose (vertex to mid-thigh, \~20-30 min). Phase 2 subset: additional scans at 15 ±5 min and 3 h ±10 min.

    Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)

Interventions

  • DrugGEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)

    Drug page: Gallium-68

    Attenuation correction CT will commence after the administration of GEH300079 (68Ga), and immediately before the PET acquisition. The PET acquisition will encompass the participant's vertex through mid-thighs. Images will be acquired at 60 ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

06

What researchers measure

Primary outcomes

  1. Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC.

    The co-primary efficacy endpoint is based on region level sensitivity and specificity of GEH300079 (68Ga) PET/CT imaging for the detection of PC in participants with colorectal, gastric or ovarian primary cancer. GEH300079 (68Ga) PET/CT images collected during the Phase 2 part will be reviewed by 5 independent readers. Images collected during the Phase 3 part will be reviewed by 3 readers. The superiority of per region sensitivity (respectively specificity) to a pre-specified threshold of 75% (respectively 70%) will be assessed using one-sided Z-tests. The co-primary endpoints will be considered as met if superiority of both per region sensitivity and per region specificity is achieved by at least 3 of the 5 readers in the Phase 2 part, and by at least 2 of the 3 readers in the Phase 3 part.

    Time frame: Single time point. Images will be acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

Secondary outcomes

  1. Superiority of the per region sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging and non-inferiority of the per region specificity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging.

    Superiority of the per region sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to SoC imaging will be assessed on participants from the ITI using a McNemar test. Non-inferiority of the per region specificity of GEH300079 (68Ga) PET/CT to detect PC compared to SoC imaging, will be assessed using a restricted maximum likelihood estimate (RMLE) -based score test, with a non-inferiority margin of 10%. SoC images will be reviewed by 3 independent readers. The co-key secondary endpoints will be met if the co-primary endpoints are met and both co-key secondary endpoints are demonstrated for the same reader, for at least 2 of the 3 pairs of readers.

    Time frame: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  2. Superiority of the per participant sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging in Phase 3

    Superiority of the per participant sensitivity of GEH300079 (68Ga) PET/CT to detect PC compared to baseline SoC imaging will be assessed using a McNemar test, in the Phase 3 part.

    Time frame: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  3. Per region PPV, NPV, and accuracy and per participant sensitivity, specificity PPV, NPV, and accuracy of GEH300079 (68Ga) PET/CT and baseline SoC imaging to detect PC

    Per region PPV, NPV, and accuracy and per participant sensitivity, specificity PPV, NPV, and accuracy of GEH300079 (68Ga) PET/CT and baseline SoC imaging to detect PC will be tabulated.

    Time frame: Single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  4. Correlation between radiological and surgical/laparoscopic PCI scores

    Correlation between radiological PCI scores (based on GEH300079 (68Ga) PET/CT, CT, MR, \[18F\]FDG PET/CT) and surgical/laparoscopic PCI score.

    Time frame: Single time point. Baseline SoC images. GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes. Surgery/laparoscopy within 28 days post injection

  5. The number of Positive peritoneal regions and percentage of participants with a difference in the number of Positive peritoneal regions.

    The number of Positive peritoneal regions identified by GEH300079 (68Ga) PET/CT, CT, MR, and \[18F\]FDG PET/CT, and the percentage of participants with a difference in the number of Positive peritoneal regions identified by GEH300079 (68Ga) PET/CT and baseline SoC imaging.

    Time frame: single time point. Baseline SoC images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  6. SUVmax of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT.

    SUVmax of GEH300079 (68Ga) PET/CT for the largest lesion identified within each peritoneal region from different primary cancers in comparison with \[18F\]FDG PET/CT.

    Time frame: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  7. SUVmean of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT.

    SUVmean of GEH300079 (68Ga) PET/CT for the largest lesion identified within each peritoneal region from different primary cancers in comparison with \[18F\]FDG PET/CT.

    Time frame: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  8. SUVpeak of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT.

    SUVpeak of GEH300079 (68Ga) PET/CT for the largest lesion identified within each peritoneal region from different primary cancers in comparison with \[18F\]FDG PET/CT.

    Time frame: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  9. Tumor to-background ratio (TBR) of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT.

    TBR of GEH300079 (68Ga) PET/CT for the largest lesion identified within each peritoneal region from different primary cancers in comparison with \[18F\]FDG PET/CT.

    Time frame: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  10. Contrast-to-noise ratio (CNR) of GEH300079 (68Ga) PET/CT in comparison with [18F]FDG PET/CT.

    CNR of GEH300079 (68Ga) PET/CT for the largest lesion identified within each peritoneal region from different primary cancers in comparison with \[18F\]FDG PET/CT.

    Time frame: Single time point Baseline [18F]FDG PET/CT images vs GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

  11. Correlation between FAP expression and GEH300079 (68Ga) PET/CT uptake in PC from different primary cancer in Phase 2

    The correlation between GEH300079 (68Ga) PET/CT uptake in PC from different primary cancers and FAP expression measured by IHC in Phase 2.

    Time frame: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes. Surgery/laparoscopy within 28 days post injection

  12. Percentage of participants for whom GEH300079 (68Ga) PET/CT could have led to a change in treatment plan

    Time frame: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection

  13. Percentage of locoregional to systemic (M0 to M1) upstaging induced by GEH300079 (68Ga) PET/CT

    Time frame: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection

  14. GEH300079 (68Ga) PET/CT image quality at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities.

    Visual assessment score of overall image quality at 15 ±5 minutes, 60 ±5 minutes, and 3 hours ±10 minutes post-injection, and across different simulated injected activities

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  15. Tumor to-background ratio (TBR) of GEH300079 (68Ga) PET/CT at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities

    TBR for each GEH300079 (68Ga) PET/CT time point and each simulated injected activity

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  16. Contrast-to-noise ratio (CNR) of GEH300079 (68Ga) PET/CT TBR at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities.

    CNR for each GEH300079 (68Ga) PET/CT time point and each simulated injected activity

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  17. Number of lesions detected by GEH300079 (68Ga) PET/CT at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities.

    Count of lesions (\<2 cm, ≥2 cm) for each GEH300079 (68Ga) PET/CT time point and each simulated injected activity

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  18. Size of lesions detected by GEH300079 (68Ga) PET/CT at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities.

    Size of lesions for each GEH300079 (68Ga) PET/CT time point and each simulated injected activity

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  19. Coefficient of Variation (CV) of GEH300079 (68Ga) PET/CT SUV in Background and Reference Tissues at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection, as well as for different simulated injected activities.

    Variation coefficient of SUV in local background and reference tissues for each GEH300079 (68Ga) PET/CT time point and each simulated injected activity

    Time frame: GEH300079 (68Ga) PET/CT Images acquired at 15 ±5 minutes, 60 ±5 minutes, and 3 hour ±10 minutes post-injection

  20. Intra-reader reproducibility for GEH300079 (68Ga) PET/CT

    Cohen's kappa statistics with 95% CI for read vs re-read, for each of the readers.

    Time frame: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection

  21. Inter-reader agreement for GEH300079 (68Ga) PET/CT

    Cohen's kappa statistics with 95% CI for the assessment of agreement between 2 readers. Fleiss's kappa statistics with 95% CI will be provided for the assessment across the readers.

    Time frame: Single time point GEH300079 (68Ga) PET/CT Images acquired at 60 minutes ±5 minutes post injection

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jun 2029, 32 months later.

Of 36 phase 2/3 interventional studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 105. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2025
First posted
Oct 21, 2025
StartEst.
Oct 2026
Primary completionEst.
Jun 2029
CompletionEst.
Aug 2029
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07219238
Lead sponsor
GE Healthcare
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Oct 2026 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jun 17, 2026

Study contacts

Michelle Straszacker
Contact
michelle.straszacker@gehealthcare.com
+44 7827 845147
Christopher Buckley
Contact
christopher.buckley@gehealthcare.com
+ 44 7786 701174

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion